GemVax Shares Phase 2a Supranuclear Palsy Trial Results at Neuro2024

GemVax & KAEL Co., Ltd. has announced promising results from their Phase 2a clinical trial of GV1001, a peptide drug under investigation for the treatment of progressive supranuclear palsy (PSP). The findings were shared at the "Neuro2024: The PSP and CBD International Research Symposium" in Toronto, Canada, on October 24th.

PSP is a rare neurodegenerative disorder characterized by symptoms such as imbalance, eye movement abnormalities, and cognitive impairment. Currently, there are no approved treatments specifically for PSP, making the development of GV1001 particularly significant.

The Phase 2a PSP Clinical Trial assessed the efficacy and safety of GV1001 in patients diagnosed with PSP. The trial's topline results revealed that GV1001 has potential as a treatment for PSP, supporting the advancement to a Phase 3 trial. The clinical trial used the PSP-Rating Scale (PSP-RS) to measure the severity and progression of the disease in participants.

During the symposium, the data presented highlighted several key points. Firstly, the PSP-RS Total Score, which includes both PSP-RS Type and PSP-P Type, showed a significant improvement in patients treated with GV1001. This was demonstrated through the least squares (LS) mean using the mixed model for repeated measures (MMRM). Secondly, a simple average of the PSP-RS Total Score also indicated positive results for the treatment group compared to the control group. Lastly, the responder rate, reflecting the proportion of patients who showed a marked improvement, was significantly higher in the GV1001-treated group.

These findings suggest that GV1001 not only slows the progression of PSP but also improves the overall condition of patients. The positive outcomes from the Phase 2a trial provide a strong foundation for moving forward with Phase 3 clinical trials, which will involve a larger patient population and further assess the drug's efficacy and safety.

GemVax & KAEL is optimistic about the potential of GV1001 to become the first approved treatment for PSP, given the encouraging results from the Phase 2a trial. The company remains committed to advancing the development of GV1001, aiming to address the unmet medical needs of patients suffering from this debilitating disease.

The presentation of these results at an international symposium underscores the significance of the findings within the scientific community and highlights the progress being made in the field of neurodegenerative disease research. As the company prepares for the next phase of clinical trials, there is hope that GV1001 could offer a new therapeutic option for PSP patients, improving their quality of life and offering a beacon of hope for those affected by this challenging condition.

In summary, the topline results from the Phase 2a clinical trial of GV1001 in PSP patients are promising, indicating the potential of the drug to slow disease progression and improve patient outcomes. With plans to advance to Phase 3 trials, GemVax & KAEL is poised to continue its efforts in developing GV1001 as a groundbreaking treatment for PSP.